Exploring Atypical Antipsychotics as an Augmentation Option for Major Depressive Disorder
neuroscienceCME TV
Premiere Date: Wednesday, December 12, 2007This activity offers CE credit for:
- Physicians (ACCME/AMA PRA Category 1)
- Nurses (CNE)
- Pharmacists (ACPE)
- Psychologists (APA)
- Social Workers (NASW)
- Certified Case Managers (CCMC)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Friday, December 12, 2008
Note: Credit Is No Longer Available
 | Ned H. Kalin, MD Hedberg Professor and Chair Department of Psychiatry University of Wisconsin School of Medicine and Public Health--Madison Director, HealthEmotions Research Institute Madison, WI Editor-in-Chief – American Journal of Psychiatry |
 | J. Alexander Bodkin, MD Assistant Professor of Psychiatry Harvard Medical School Director, Clinical Psychopharmacology Research Program McLean Hospital Boston, MA |
 | Mark Hyman Rapaport, MD Chairman, Department of Psychiatry and Behavioral Sciences Emory University School of Medicine Chief of Psychiatric Services Emory Healthcare System Atlanta, GA |
Major depressive disorder is a debilitating affective disorder associated with significant morbidity and mortality.
Numerous treatment options with varying mechanisms of action exist, but the biological heterogeneity of this
condition often results in differential patient responses. Understanding the neurobiology of depression is critical
to identifying optimal treatment strategies for each patient.
Although there are a variety of nonpharmacologic and pharmacologic treatment strategies, data from the
NIMH-sponsored Sequenced Treatment Alternatives to Relieve Depression (STAR*D) indicate that only one-third
of patients achieve remission with an initial therapy.(1) These findings illustrate the need for safe and effective
alternate treatments that improve outcomes in patients with major depressive disorder. Atypical antipsychotics
may represent an augmentation option for patients who fail to respond to traditional therapies. In this live,
evidence-based neuroscienceCME TV activity, the experts will review the neurobiology of depression and
remission rates for current therapies, and explore alternate strategies for the management of depression.
- Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28-40.
To examine the neurobiology of depression, evaluate the effectiveness of traditional antidepressant medications, and explore atypical antipsychotics as an augmentation option for patients that do not remit with traditional antidepressant therapies.
At the end of this CE activity, participants should be able to:
- Summarize the neurobiological substrates of depression and the mechanisms of action of alternate pharmacologic strategies.
- Evaluate remission rates for standard antidepressant therapies used in the management of depression.
- Analyze the efficacy and safety of atypical antipsychotics as adjunctive therapy for the treatment of major depressive disorder.
CME Outfitters, LLC, and CME LLC gratefully acknowledge an educational grant from Bristol-Myers Squibb Company and Otsuka America Pharmaceuticals, Inc., in support of this CE activity.
Physicians, physician assistants, nurse practitioners, nurses, psychologists, social workers, certified case managers, pharmacists, and other healthcare professionals with an interest in mental health.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited
by the Accreditation Council for Continuing
Medical Education to provide continuing
medical education for physicians.
CME Outfitters, LLC, designates this educational activity for
a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians
should only claim credit commensurate with the extent of
their participation in the activity.
CNE Credit (Nurses):
CME Outfitters, LLC, is an approved
provider of continuing nursing education by the New York
State Nurses Association, an accredited approver by the
American Nurses Credentialing Center’s Commission on
Accreditation.
It has been assigned code 6WASUP-PRV-0622. 1.0 contact
hours will be awarded upon successful completion. This
activity is co-provided with CME LLC.
Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.
CEP Credit (Psychologists):
CME Outfitters is approved
by the American Psychological Association to sponsor
continuing education for psychologists. CME Outfitters
maintains responsibility for this program and its content.
(1.0 CE credits)
NASW Credit (Social Workers):
This program was approved
by the National Association of Social Workers (provider
#886407722) for 1 continuing education contact hour.
CCMC Credit (Certified Case Managers):
This program
has been approved for 1 hour by the Commission for Case
Manager Certification (CCMC).
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited
by the Accreditation Council for Pharmacy Education
as a provider of continuing pharmacy education.
1.0 contact hours (0.1 CEUs)
Universal Program Number:
376-999-07-022-L01-P (live presentation)
376-999-07-022-H01-P (recorded programs)
Post-tests, credit request forms, and activity evaluations can be
completed online at www.neuroscienceCME.com (click on the
Testing/Certification link under the Resources tab - requires free
account activation), and participants can print their certificate
or statement of credit immediately (70% pass rate required).
Otherwise, participants should fully complete and return both
the credit request form and activity evaluation located within the
course guide for this activity. A certificate or statement of credit
will be mailed within 4-6 weeks to all who successfully complete
these requirements.
J. Alexander Bodkin, MD
Dr. Bodkin is Assistant Professor in the Department of Psychiatry at Harvard Medical School, Boston, MA. He serves as Chief of the
Clinical Psychopharmacology Research Program at the McLean Hospital in Belmont, MA.
Dr. Bodkin studied Philosophy as an undergraduate at Columbia, Medicine at Yale, and completed a psychiatric residency and a
postgraduate research fellowship in Affective Disease at McLean Hospital, where he has remained ever since.
He divides his time between research in clinical psychopharmacology, teaching psychiatry residents and medical students, and
a private consulting practice. He has published extensively in a variety of areas in psychiatric therapeutics and diagnosis, with a
particular interest in the clinical psychopharmacology of refractory depression. In 2002 he authored the first paper demonstrating
the effectiveness of transdermally administered selegiline in the acute treatment of major depression. In 2006 he coauthored the
first report of the efficacy of transdermal selegiline in preventing depressive relapse.
Mark Hyman Rapaport, MD
Dr. Rapaport is Chairman of the Department of Psychiatry and Mental Health at Cedars-Sinai Medical Center and is the recipient
of The Polier Endowed Chair in Schizophrenia and Related Disorders. Dr. Rapaport is also Vice Chair of the Department of
Psychiatry and Professor of Psychiatry at University of California, Los Angeles (UCLA). Before coming to Cedars-Sinai, he served as Director of the Mental Health Outpatient Clinical Research Center in the Department of Psychiatry at University of California, San
Diego (UCSD).
Dr. Rapaport has received peer-reviewed grant funding from the National Institute of Mental Health (NIMH), National Center
for Complimentary and Alternative Medicine, The Stanley Medical Research Institute, the Veterans Affairs Research Board and
the National Alliance for Research on Schizophrenia and Depression (NARSAD) Foundation. His research interests are focused
on psychopharmacology, and he has investigated the biologic genesis of anxiety disorders, bipolar disorder, depression and
immunity abnormalities in schizophrenia. Dr. Rapaport has served as a consultant to more than 20 pharmaceutical companies to
help develop promising new drug therapies, and he has trained and mentored students, physicians and researchers in the field of
psychopharmacology. He was previously first Chair of the National Institute on Drug Abuse (NIDA) Clinical Trials Network’s Data
Safety Monitoring Board and Chair of its Special Review Committee. He has served on NIH and NIMH Review Committees.
A board-certified psychiatrist, Dr. Rapaport has written over 167 articles for such peer-reviewed publications as American Journal
of Psychiatry, Biological Psychiatry, Journal of Clinical Psychiatry, and Neuropsychopharmacology. He currently serves as Co-Editor
and Chief of FOCUS: The Journal of Lifelong Learning in Psychiatry, published by American Psychiatric Publishing, Inc. and the
American Psychiatric Association. Dr. Rapaport is a member of the American College of Psychiatrists, American Society of Clinical
Psychopharmacology, Anxiety Disorders Association of America, the Psychiatric Research Society and the Collegium International
Neuropsychopharmacology (CINP). He is a Distringuished Fellow of the American Psychiatric Association, the CINP, and the
American College of Neuropsychopharmacology (ACNP).
Dr. Rapaport received his bachelor’s degree from Revelle College at the University of California, San Diego (UCSD) and his medical
degree from UCSD School of Medicine. He completed an internship in internal medicine at Long Beach Veterans Administration
and University of California, Irvine Medical Center and a psychiatry residency at UCSD. He also completed a research fellowship at
UCSD’s Department of Psychiatry and a clinical fellowship at the National Institute of Mental Health in Bethesda, Maryland, where
he later served as a guest researcher.
Ned H. Kalin, MD, Moderator
Dr. Kalin is Hedberg Professor and Chairman of the Department of Psychiatry at the University of Wisconsin School of Medicine
and Public Health. He is Director of HealthEmotions Research Institute and Professor in the Department of Psychology at
the University of Wisconsin. Dr. Kalin is an affiliate scientist at the Wisconsin Regional Primate Center and the Harlow Primate
Laboratory. He serves as the principal investigator for several ongoing research projects, consults to the pharmaceutical
industry, and founded a biotechnology company, Promoter Neurosciences, aimed at developing novel treatments for psychiatric
disorders. His research focuses on uncovering basic mechanisms relating stress to the development of psychopathology and to
understanding the adaptive and maladaptive regulation of emotion.
Dr. Kalin earned his medical degree from Jefferson Medical School in Philadelphia, Pennsylvania. He then did a residency in the
Department of Psychiatry at the University of Wisconsin. Subsequently, he did a fellowship in Neuropsychopharmacology at
the National Institute of Mental Health. Dr. Kalin is board certified by the American Boards of Psychiatry and Neurology. He has
published over one hundred and fifty peer-reviewed research papers and is Co-Editor of Psychoneuroendocrinology. He lectures
regularly at national and international meetings. He is a fellow of the American College of Neuropsychopharmacology and the
American College of Psychiatry. He has been recognized for numerous awards including the 1985 A.E. Bennett Award for basic
science research in biological psychiatry, the 2005 Edward A. Strecker Award, the 2007 American College of Psychiatrists Award
for research in mood disorders, and most recently the 2007 Gerald Klerman Senior Investigator Award. He is president of the
International Society of Psychoneuroendocrinology and recently served on the National Advisory Mental Health Council.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all its CE
activities. Faculty must disclose to the participants any significant relationships with commercial companies whose products or
devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has
evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure,
use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant
information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Bodkin has disclosed that he receives research support from Eli Lilly and Company, Merck, Ono Pharmaceuticals, Pfizer Inc.,
and Sanofi. He is on the speakers bureau of and serves as a consultant to Bristol-Myers Squibb Company.
Dr. Rapaport has disclosed that he receives research support/grants from AstraZeneca, NCCAM, NIMH, and Solvay
Pharmaceuticals. He is on the speakers bureaus of Forest Laboratories and Wyeth Pharmaceuticals. Dr. Rapaport serves
as a consultant to Brain Cells, Inc., Cyberonics, Inc., Janssen L.P., NCCR, NIMH, Pfizer Inc., Schwarz Pharmaceuticals, Solvay
Pharmaceuticals, and Wyeth Pharmaceuticals.
Dr. Kalin has disclosed that he serves as a consultant to AstraZeneca, Bristol-Myers Squibb Company, CeNeRx Biopharma,
Corcept Therapeutics, Cowen and Company, LLC, Cyberonics, Cypress Biosciences, Eli Lilly and Company, Forest Laboratories,
General Electric Corp., GlaxoSmithKline, Janssen L.P., Johnson and Johnson, Neurocrine Biosciences, Neuronetics, Novartis, Sanofi-
Synthelabo, Skyland Trail, and Wyeth Research. He is a stockholder or has equity in CeNeRx, Corcept Therapeutics, and Neurocrine
Biosciences.
Unlabeled Use Disclosure
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The
faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational
uses (any uses not approved by the FDA) of products or devices.
CME Outfitters, LLC, and CME LLC, the faculty, Bristol-Myers Squibb Company, and Otsuka America Pharmaceuticals, Inc., do not
endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures,
products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or
dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
TV-051-121207-08
